| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 11,009 | 3,056 | 2,754 | 12,598 |
| Research and development | 12,182 | 16,218 | 18,341 | 14,803 |
| General and administrative | 6,303 | 7,415 | 8,925 | 9,864 |
| Restructuring expenses | 191 | 3,940 | - | - |
| Total operating expenses | 18,676 | 27,573 | 27,266 | 24,667 |
| Interest income | 516 | 895 | 1,164 | 1,972 |
| Interest expense | 394 | 674 | 775 | 986 |
| Total other income, net | 122 | 221 | 389 | 986 |
| Loss before income taxes | -7,545 | - | - | -11,083 |
| Income tax expense | 0 | - | - | 418 |
| Net loss | -7,545 | -24,296 | -24,123 | -11,501 |
| Unrealized gain (loss) on marketable securities, net of tax | 0 | 0 | -10 | 96 |
| Comprehensive loss | -7,545 | -24,296 | -24,133 | -11,405 |
| Net loss per share attributable to common stockholders basic (in dollars per share) | -1.51 | -4.87 | -0.19 | -0.09 |
| Net loss per share attributable to common stockholders diluted (in dollars per share) | -1.51 | -4.87 | -0.19 | -0.09 |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders basic (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | 122,721,918 |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders diluted (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | 122,721,918 |
Mersana Therapeutics, Inc. (MRSN)
Mersana Therapeutics, Inc. (MRSN)